Call Scheduled for Tuesday, November 4, 2003 at 4:30 P.M. Will Detail Findings
Related to Study of HDL Therapy in Treatment of Atherosclerosis
ANN ARBOR, Mich., Nov. 3 /PRNewswire-FirstCall/ -- Esperion Therapeutics,
Inc. will hold a conference call to provide detailed findings related to the
Company's Phase 2 clinical trial for ETC-216 for the treatment of
atherosclerosis. The call is scheduled for Tuesday, November 4, 2003 at 4:30
PM and will be led by Roger S. Newton, Ph.D., President and CEO of Esperion.
In initial study results presented in June 2003, the Company announced
that ETC-216 demonstrated statistically significant reduction in percent
atherosclerotic plaque volume among acute coronary syndrome patients.
The Company as well as the study's principal investigator, Steven E.
Nissen, M.D., F.A.C.C., medical director of the Cleveland Clinic
Cardiovascular Coordinating Center, continue to confirm the positive results
of the study, which showed for the first time that ETC-216 is able to reverse
the course of atherosclerotic disease in acute coronary syndrome patients at
the end of six weeks. The full data from the study have not been released and
remain under embargo until 4:00 p.m. on Tuesday, November 4. Esperion
continues to honor the publication embargo and will not comment on rumors or
assumptions related to the full data set until after the embargo has been
lifted in accordance with standard accepted practices related to publication
of data in a peer-reviewed setting.
What: Esperion Conference Call on ETC-216 Study Findings
When: Tuesday, November 4, 2003 at 4:30 p.m. (ET)
Via Telephone: From U.S. and Canada, dial (800) 901-5226
From other locations, dial (617) 786-4513
All callers should give the conference ID "Esperion"
when prompted
Via Internet: Visit http://www.esperion.com, click on the Investor
Relations link, and then click on the Calendar link
shortly before 4:30 p.m. (ET)
A replay of the Esperion conference call will be available beginning at
8:00 p.m. (ET) on November 4, 2003 until 11:59 p.m. (ET) on November 11, 2003.
To access the replay from the U.S. and Canada, dial (888) 286-8010 and enter
passcode #92056812. From all other locations, dial (617) 801-6888 and enter
passcode #92056812. To access the replay via the Internet, visit
http://www.esperion.com, click on the Investor Relations link, and then click
on the Audio/Visual Archives link.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of
high-density lipoprotein, or HDL, function. HDL is the primary facilitator of
the RLT pathway by which excess cholesterol and other lipids are removed from
arteries and other tissues and are transported to the liver for elimination
from the body. Esperion's goal is to develop drugs that exploit the
beneficial functions of HDL within the RLT pathway. Esperion currently has
four product candidates in clinical development. Esperion is listed on the
Nasdaq National Market under the symbol "ESPR." For more information, visit
http://www.esperion.com.
Safe Harbor Statement
The information contained in this press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are often identified by words such
as "hope," "may," "believe," "anticipate," "plan," "expect," "require,"
"intend," "assume" and similar expressions. Forward-looking statements speak
only as of the date of this press release, reflect management's current
expectations, estimations and projections and involve certain factors, such as
risks and uncertainties, that may cause actual results, performance or
achievements to be far different from those suggested by the Company's
forward-looking statements. These factors include, but are not limited to,
risks associated with: the Company's ability to successfully execute its
business strategies, including entering into strategic partnerships or other
transactions; the progress and cost of development of the Company's product
candidates; the extent and timing of market acceptance of new products
developed by the Company or its competitors; the Company's dependence on third
parties to conduct clinical trials for the Company's product candidates; the
extent and timing of regulatory approval, as desired or required, for the
Company's product candidates; the Company's dependence on licensing
arrangements and strategic relationships with third parties; clinical trials;
manufacturing; the Company's dependence on patents and proprietary rights;
litigation, proceedings, investigations and other disruptions of management's
time resulting from the acquisition of the Company's common stock by various
persons associated with Scott Sacane; the procurement, maintenance,
enforcement and defense of the Company's patents and proprietary rights;
competitive conditions in the industry; business cycles affecting the markets
in which any of the Company's future products may be sold; extraordinary
events and transactions; seeking and consummating business acquisitions,
including the diversion of management's attention to the assimilation of the
operations and personnel of any acquired business; the timing and extent of
the Company's financing needs and the Company's access to funding, including
through the equity market, particularly in light of the impact on the market
value of the Company's common stock of matters outside of the Company's
control, such as trading activities by third parties; fluctuations in foreign
exchange rates; and economic conditions generally or in various geographic
areas. Because all of the foregoing factors are difficult to forecast, you
should not place undue reliance on any forward-looking statement. More
detailed information about some of these and other risk factors is set forth
in the Company's filings with the Securities and Exchange Commission. The
Company does not intend to update any of these factors or to publicly announce
the results of any revisions to any of these forward-looking statements other
than as required under the federal securities laws.
Company Amy Cannon
Contact: Manager, Corporate Communications
Esperion Therapeutics, Inc.
(734) 222-1801
acannon@esperion.com
Media Jim Wetmore
Contact: Berry & Company Public Relations
(212) 253-8881
jwetmore@berrypr.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
CONTACT:
Amy Cannon, Manager, Corporate Communications
of Esperion Therapeutics, Inc., +1-734-222-1801,
acannon@esperion.com; or Jim Wetmore of Berry & Company Public,
+1-212-253-8881, jwetmore@berrypr.com, for Esperion Therapeutics,
Inc.
|
